165 related articles for article (PubMed ID: 31882503)
21. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer.
Twelves C; Chmielowska E; Havel L; Popat S; Swieboda-Sadlej A; Sawrycki P; Bycott P; Ingrosso A; Kim S; Williams JA; Chen C; Olszanski AJ; de Besi P; Schiller JH
Ann Oncol; 2014 Jan; 25(1):132-8. PubMed ID: 24356624
[TBL] [Abstract][Full Text] [Related]
22. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Zhou C; Wu YL; Chen G; Liu X; Zhu Y; Lu S; Feng J; He J; Han B; Wang J; Jiang G; Hu C; Zhang H; Cheng G; Song X; Lu Y; Pan H; Zheng W; Yin AY
J Clin Oncol; 2015 Jul; 33(19):2197-204. PubMed ID: 26014294
[TBL] [Abstract][Full Text] [Related]
23. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.
Socinski MA; Scappaticci FA; Samant M; Kolb MM; Kozloff MF
J Thorac Oncol; 2010 Mar; 5(3):354-60. PubMed ID: 20032789
[TBL] [Abstract][Full Text] [Related]
25. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
26. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
27. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
28. Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.
Fujimoto K; Watanabe S; Yasuda Y; Date E; Kawabata Y; Kanemura H; Takahama T; Yonesaka K; Iizuka N; Takahashi KI; Kawakami O; Ozaki T; Nakagawa K
Thorac Cancer; 2023 Jan; 14(2):214-217. PubMed ID: 36495048
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.
van den Ende T; Menting SP; Ambarus CA; van Oijen MGH; van Laarhoven HWM
Oncologist; 2019 Apr; 24(4):e149-e153. PubMed ID: 30902915
[TBL] [Abstract][Full Text] [Related]
30. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
[TBL] [Abstract][Full Text] [Related]
31. [A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab].
Suzuki E; Tanahashi M; Yukiue H; Yoshii N; Shitara M; Fujino T; Niwa H
Gan To Kagaku Ryoho; 2016 May; 43(5):617-20. PubMed ID: 27210094
[TBL] [Abstract][Full Text] [Related]
32. Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
Endo K; Tanaka H; Matsuo H; Onoda T; Iida A; Ishii T
Anticancer Res; 2024 Jun; 44(6):2653-2660. PubMed ID: 38821611
[TBL] [Abstract][Full Text] [Related]
33. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
[TBL] [Abstract][Full Text] [Related]
35. Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia.
Rubovszky G; Nagy T; Gődény M; Szász A; Láng I
Pathol Oncol Res; 2013 Jan; 19(1):119-22. PubMed ID: 22752712
[TBL] [Abstract][Full Text] [Related]
36. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
37. Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA
Anticancer Drugs; 2019 Nov; 30(10):1067-1070. PubMed ID: 31567311
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
39. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
Garcia D; Mambetsariev I; Fricke J; Schmolze D; Afkhami M; Mannan R; Kim P; Therese Dingal S; Nguyen B; Babikian R; Fong Y; Salgia R
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37160318
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.
Reck M; Krzakowski M; Chmielowska E; Sebastian M; Hadler D; Fox T; Wang Q; Greenberg J; Beckman RA; von Pawel J
Lung Cancer; 2013 Dec; 82(3):441-8. PubMed ID: 24148258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
